JournalsHub
.online
Find My Journal
NC

Nicola J. Curtis

AstraZeneca (Singapore) SG

20
Publications
489
Citations
7
H-Index
7
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

20 total

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma PDF

Nicolas Floc’h, Susan Ashton, Douglas Ferguson, Paula Taylor, Larissa S. Carnevalli et al. - Molecular Cancer Therapeutics, 2019
Cited by 22 OpenAlex

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity PDF

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft, Filippos Michopoulos, Nichola Whalley et al. - Oncotarget, 2017
Cited by 151 OpenAlex

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles PDF

Nicolas Floc’h, Susan Ashton, Paula Taylor, Dawn Trueman, Emily Harris et al. - Molecular Cancer Therapeutics, 2017
Cited by 36 OpenAlex

A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors PDF

Stephen A. St-Gallay, Neil Bennett, Susan E. Critchlow, Nicola J. Curtis, Gareth M. Davies et al. - SLAS DISCOVERY, 2017
Cited by 14 OpenAlex

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3 PDF

Scott Boyd, Joanna Brookfield, Susan E. Critchlow, Iain Cumming, Nicola J. Curtis et al. - Journal of Medicinal Chemistry, 2015
Cited by 93 OpenAlex

Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1)

Susan E. Critchlow, Lorna Hopcroft, Lorraine Mooney, Nicola J. Curtis, Nicky Whalley et al. - Cancer Research, 2012
Cited by 13 OpenAlex

The ABC Transporter AnrAB Contributes to the Innate Resistance of <i>Listeria monocytogenes</i> to Nisin, Bacitracin, and Various β-Lactam Antibiotics PDF

Barry Collins, Nicola J. Curtis, Paul D. Cotter, Colin Hill, R. Paul Ross - Antimicrobial Agents and Chemotherapy, 2010
Cited by 154 OpenAlex

Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials

Eli Wallace, Joseph P. Lyssikatos, James F. Blake, Allison Marlow, Julie Greschuk et al. - Cancer Research, 2009
Cited by 4 OpenAlex

Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration

Robert W. Wilkinson, Armelle Logié, Nicola Haupt, Nicola J. Curtis, Mark Hickinson et al. - Cancer Research, 2008
Cited by 2 OpenAlex

Research Topics

Microtubule and mitosis dynamics (11) Cancer, Hypoxia, and Metabolism (10) Protein Degradation and Inhibitors (5) Acute Myeloid Leukemia Research (3) Nanoparticle-Based Drug Delivery (2)

Affiliations

AstraZeneca (United Kingdom)
GB 2019 - 2008
University College Cork
IE 2010 - 2010
AstraZeneca (Singapore)
SG 2026 - 2017

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now